The debate on antifibrinolytics in liver transplantation: always, never, or sometimes?
Eduarda S. Martinelli, Stuart A. McCluskey, Keyvan Karkouti, Carla A. Luzzi, Matthanja Bieze, Luiz Marcelo S. Malbouisson, André P. Schmidt
References
1. Massicotte L, Lenis S, Thibeault L, Sassine MP, Seal RF, Roy A. Effect of low central venous pressure and phlebotomy on blood product transfusion requirements during liver transplantations. Liver Transplantation. 2006;12:117−23.
2. Gorlinger K, P € erez-Ferrer A, Dirkmann D, et al. The role of evidence-based algorithms for rotational thromboelastometryguided bleeding management. Korean J Anesthesiol. 2019;72: 297−322.
3. Cleland S, Corredor C, Ye JJ, Srinivas C, McCluskey SA. Massive haemorrhage in liver transplantation: Consequences, prediction and management. World J Transplant. 2016;6:291.
4. Cardenas JC, Matijevic N, Baer LA, Holcomb JB, Cotton BA, Wade CE. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients. Shock. 2014;41:514−21.
5. Pabinger I, Fries D, Schochl H, Streif W, Toller W. Tranexamic € acid for treatment and prophylaxis of bleeding and hyperfibrinolysis. Wien Klin Wochenschr. 2017;129:303−16.
6. Fergusson DA, Hebert PC, Mazer CD, et al. A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery. New Engl J Med. 2008;358:2319−31.
7. Yoon U, Bartoszko J, Bezinover D, et al. Intraoperative transfusion management, antifibrinolytic therapy, coagulation monitoring and the impact on short-term outcomes after liver transplantation—A systematic review of the literature and expert panel recommendations. Clin Transplant. 2022;36:e14637.
8. Nicolau-Raducu R, Ku TC, Ganier DR, et al. Epsilon-Aminocaproic Acid Has No Association With Thromboembolic Complications, Renal Failure, or Mortality After Liver Transplantation. J Cardiothorac Vasc Anesth. 2016;30:917−23.
9. Kietaibl S, Ahmed A, Afshari A, et al. Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care: Second update 2022. Eur J Anaesthesiol. 2023;40:226−304.
10. Colomina MJ, Contreras L, Guilabert P, Koo M, M.ndez E, Sabate A. Clinical use of tranexamic acid: evidences and controversies. Braz J Anesthesiol. 2022;72:795−812.
11. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30:270−382.
12. Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: A randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess (Rockv). 2013;17:1−80.
13. Shakur H, Roberts I, Fawole B, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389:2105−16.
14. Assis I de C, Goveia CS, Miranda DB, Ferreira RS, Riccio LGC. ^ Analysis of the efficacy of prophylactic tranexamic acid in preventing postpartum bleeding: systematic review with metaanalysis of randomized clinical trials. Braz J Anesthesiol. 2023;73:467−76.
15. Myles PS, Smith JA, Forbes A, et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017;376: 136−48.
16. Shi J, Zhou C, Pan W, et al. Effect of High-vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial. JAMA. 2022;328:336−47.
17. Elwatidy S, Jamjoom Z, Elgamal E, Zakaria A, Turkistani A, El-Dawlatly A. Efficacy and Safety of Prophylactic Large Dose of Tranexamic Acid in Spine Surgery A Prospective, Randomized, Double-Blind, Placebo-Controlled Study. Spine (Phila Pa 1976). 2008;33:2577−80.
18. Garcia T, Fragao-Marques M, Piment ~ ao P, Pinto M, Pedro I, Mar- ~ tins C. Tranexamic acid in total shoulder arthroplasty under regional anesthesia: a randomized, single blinded, controlled trial. Braz J Anesthesiol. 2022;72:220−7.
19. Devereaux PJ, Marcucci M, Painter TW, et al. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med. 2022;386:1986−97.
20. de Brito RM, de Oliveira CMB, Moura ECR, et al. Comparison of tranexamic acid and stapling line reinforcement in laparoscopic sleeve gastrectomy in postoperative bleeding outcomes. Braz J Anesthesiol. 2023;73:361−3.
21. Trial Collaborators HALT-IT. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:1927−36.
22. Karanicolas PJ, Lin Y, McCluskey SA, et al. Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial. JAMA. 2024:e2411783.
23. Houston BL, Uminski K, Mutter T, et al. Efficacy and Safety of Tranexamic Acid in Major Non-Cardiac Surgeries at High Risk for Transfusion: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2020;34:51−62.
24. Badenoch A, Sharma A, Gower S, et al. The Effectiveness and Safety of Tranexamic Acid in Orthotopic Liver Transplantation Clinical Practice: A Propensity Score Matched Cohort Study. Transplantation. 2017;101:1658−65.
25. Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR. Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database Syst Rev. 2011;2011:CD009052.
26. Bezinover D, Dirkmann D, Findlay J, et al. Perioperative coagulation management in liver transplant recipients. Transplantation. 2018;102:578−92.
27. Ng W, Jerath A, Wasowicz M. Tranexamic acid: A clinical review. Anaesthesiol Intensive Ther. 2015;47:339−50.